however, despite these already broad recommendations for influenza vaccination, only about half of high-risk individuals typically receive the vaccine, according to the cdc. additionally, the acip noted that emerging data indicate that persons aged 19 to 49 years have been particularly vulnerable to ...
Note: for the 2024-2025 season, the CDC recommends either the inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or the LAIV (intranasal). All vaccine formulations will be trivalent for the 2024-2025 influenza season. Quadrivalent vaccines are no longer produced as the influe...
Updated recommendations for this season include vaccine dosing for children aged 6 months through 8 years, and use of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) when either is available, including removal of the 2015-2015 preferential recommendation for LAIV for ...
ACIP’s 2023-2024 influenza vaccination guidance maintained the same recommendation that has been central to the group’s guidance since 2010: All persons 6 months and older without any medical contraindications should receive the seasonal influenza vaccine when available.3 Vaccination is not recommended...
recommendation is based on studies showing poorer antibody response with a single dose of the vaccine among children receiving the vaccine for the first time, as well as studies showing lower vaccine effectiveness among children younger than 5 years who received 1 dose of the influenza vaccin...
In a reversal of its 2015 recommendation, the CDC Advisory Committee on Immunization Practices has voted to approve an update for the 2016-2017 season stating that the live-attenuated influenza vaccine, offered as a nasal spray, should not be used in any setting.Read more ...
At various times in recent decades, surges have occurred in optimism about the potential for universal influenza vaccines that provide strong, broad, and l
The potential for future development of these novel influenza vaccine candidates is discussed from an industry perspective.Background Seasonal influenza outbreaks cause 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths each year [1, 2]. The Orthomyxoviridae are a ...
Who have been vaccinated only within the previous 2 weeks For whom vaccination is contraindicated Who are immunocompromised and thus may not respond to vaccination Antiviral medications do not impair development of immunity from inactivated vaccine. They can be stopped 2 weeks after vaccination. If vac...
Table 4. Vaccination recommendation for adult patients. VaccineInactivated/live attenuated (I/LA)Recommended before transplantRecommended after transplantEvaluate for serologic response Influenza I Yes Yes No Influenza LA Yes No No Hepatitis I Yes Yes Yes Hepatitis Aa I Yes Yes Yes Tetanus I Yes Yes...